Tumor initiation and progression are dependent on both aberrant gene expression in tumor cells and the communication between tumor cells and its micro- and systemic microenvironment. Many tumor suppressor genes and oncogenes have been characterized to suppress or promote tumor growth, but fewer genes in tumors are well-characterized as interacting with immune cells in the host to promote or inhibit tumor growth. The interleukin (IL) 27 receptor WSX1 is expressed in immune cells and induces an IL27-dependent immune response. Opposing this conventional dogma, our initial results reveal a much higher level of WSX1 expression in multiple types of epithelial tumor cells when compared to normal epithelial cells. These revelations suggest a role for WSX1 in tumor development, and thus a possible target in cancer immune-therapy. Using genetically modified tumor cells, our studies show that the expression of WSX1 in tumor cells regulates the communication between tumor and host cells resulting in two different consequences. In both the cervical cell line TC1 and the squamous carcinoma cell line AT84, overexpression of WSX1inhibited tumorigenicity both in vivo and in vitro. Sensitizing NK cell-mediated surveillance through upregulation of NKG2D ligands in tumor cells is the underlying mechanism by which WSX1 inhibits tumor growth. Further investigations into other cell lines, such as colon cancer (CT26) and Lewis Lungs Carcinoma (LLC), confirmed the role of WSX1 as a tumor suppressor in vitro. In contrast to the role that WSX1 plays in the aforementioned cells, aggressive LLC and melanoma AGS tumor cells expressing WSX1 grow faster than the control cohorts. These studies reveal that the principal mechanism by which WSX1 promotes tumor growth is the inhibition of T cell proliferation and production of the effector cytokine IFNγ both in the tumor microenvironment and distal lymphatic tissues. Our evidence reveals that this effect is initiated via direct tumor cell and immune cell contact. This important observation reveals a new pathway of tumor-host interaction, which will ultimately lead to better strategies in immune therapy to reverse tumor tolerance.
| Identifer | oai:union.ndltd.org:LSU/oai:etd.lsu.edu:etd-04132010-110934 |
| Date | 14 April 2010 |
| Creators | Dibra, Denada |
| Contributors | Barker, Steven A., Li, Shisheng, Jeyaseelan, Samithamby, Sehgal, Inder, Li, Shulin |
| Publisher | LSU |
| Source Sets | Louisiana State University |
| Language | English |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | http://etd.lsu.edu/docs/available/etd-04132010-110934/ |
| Rights | unrestricted, I hereby certify that, if appropriate, I have obtained and attached herein a written permission statement from the owner(s) of each third party copyrighted matter to be included in my thesis, dissertation, or project report, allowing distribution as specified below. I certify that the version I submitted is the same as that approved by my advisory committee. I hereby grant to LSU or its agents the non-exclusive license to archive and make accessible, under the conditions specified below and in appropriate University policies, my thesis, dissertation, or project report in whole or in part in all forms of media, now or hereafter known. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report. |
Page generated in 0.0016 seconds